{
  "resourceType" : "Composition",
  "id" : "composition-drug-pq-risk",
  "meta" : {
    "profile" : ["http://hl7.org/fhir/uv/pharm-quality/StructureDefinition/Composition-drug-pq"]
  },
  "language" : "en",
  "text" : {
    "status" : "generated",
    "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: Composition composition-drug-pq-risk</b></p><a name=\"composition-drug-pq-risk\"> </a><a name=\"hccomposition-drug-pq-risk\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-Composition-drug-pq.html\">Composition - Drug PQ</a></p></div><p><b>status</b>: Final</p><p><b>type</b>: <span title=\"Codes:\">Product Note - Summary for Risk of Impurities</span></p><p><b>date</b>: 2023-10-01</p><p><b>author</b>: <a href=\"Organization-organization-drug-pq-ex1.html\">Organization AAA Molybdenum Products, Inc.</a></p><p><b>title</b>: 3.2.P.2.2.4 - Summary for Risk of Impurities</p></div>"
  },
  "status" : "final",
  "type" : {
    "text" : "Product Note - Summary for Risk of Impurities"
  },
  "subject" : [{
    "reference" : "MedicinalProductDefinition/medicinalproductdefinition-drug-product-pq-ex1"
  }],
  "date" : "2023-10-01",
  "author" : [{
    "reference" : "Organization/organization-drug-pq-ex1"
  }],
  "title" : "3.2.P.2.2.4 - Summary for Risk of Impurities",
  "section" : [{
    "text" : {
      "status" : "additional",
      "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Text for the risk assessment of elemental impurities in the product</p></div>"
    }
  }]
}